Transgenomic's Products and Services Play Key Role in Groundbreaking Cancer Research Presentations

Strategic Insights -

Representatives from major research institutions and pharmaceutical companies worldwide showcased the critical role of Transgenomic's products and services in their groundbreaking research presentations at the American Association of Cancer Research annual meeting in Anaheim. Researchers utilized Transgenomic's tools for various applications, including mutational analysis, methylation status, and cancer-associated mutations detection. Stan Lilleberg, PhD, Transgenomic's director of Translational and Clinical Research, highlighted the importance of incorporating genomic biomarker analyses into translational and clinical research protocols for advancing cancer therapy concepts. The company's WAVE System and SURVEYOR mutation detection kits proved to be essential in detecting low-abundance somatic mutations in clinical specimens.

Key Takeaways:

  • Transgenomic's products and services played a key role in various research presentations at the American Association of Cancer Research annual meeting in Anaheim, including mutational analysis, methylation status, and cancer-associated mutations detection.
  • Researchers utilized Transgenomic's tools for applications such as analysis of the methylation status and/or polymorphisms in genes encoding key drug-metabolizing enzymes; detection of cancer-associated mutations in DNA isolated from blood serum or plasma; analysis of genetic variation associated with cancer predisposition; and development of new analytical techniques.
  • Stan Lilleberg, PhD, emphasized the importance of incorporating genomic biomarker analyses into translational and clinical research protocols for advancing cancer therapy concepts.
  • The company's WAVE System and SURVEYOR mutation detection kits were instrumental in detecting low-abundance somatic mutations in clinical specimens, a critical component of the transition from 'bench to bedside' in cancer research.
  • Transgenomic's Discovery Services unit enabled highly sensitive mutational analysis of key signal transduction pathways in clinical specimens, providing a comprehensive set of solutions to the cancer research community.
  • Transgenomic's products and services are tailored to meet the expanding need for genomic biomarker analysis to support the development of novel diagnostic and therapeutic strategies.

Statistics:

  • Transgenomic's WAVE System has been proven to be a uniquely enabling technology for detection of low-abundance somatic mutations in various clinical specimens.
  • The SURVEOR mutation detection kits, related consumable products, and Discovery Services unit provide a comprehensive set of solutions to the cancer research community.
  • Transgenomic's products and services have been used in research presentations at the American Association of Cancer Research annual meeting in Anaheim to analyze mutational analysis of important drug targets and related genes.

Sources:

  • "Transgenomic, Inc.", Health & Medicine Week, NewsRx.com, (No specific date mentioned)
  • Transgenomic's CEO, Collin D'Silva, quoted in Health & Medicine Week, NewsRx.com, (No specific date mentioned)